11:36 AM EST - Amorfix Life Sciences Ltd. : announced today that it is offering the EP-AD assay service to customers and that a number of pharmaceutical companies are currently evaluating the test in several pilot studies. In a study conducted by the Company, the ED-AD CSF test was more sensitive at identifying individuals with MCI (94% sensitivity) than current biomarkers (monomeric Abeta 42 and phospho-tau). The Amorfix diagnostic offers several distinct advantages over the other tests. It measures small aggregates of Abeta (called oligomers) which are thought to be responsible for the major part of Abeta toxicity, and are regarded as the most relevant molecule in disease pathogenesis. In addition, the ED-AD CSF test can identify early-stage patients before they progress into frank AD. Amorfix Life Sciences Ltd.
shares T.AMF are trading up $0.02 at $0.42.
